To include your compound in the COVID-19 Resource Center, submit it here.

SCIO-469 (31145): Began Phase I trial

(Preclinical results, B16)

Scios Inc. (SCIO), Sunnyvale, Calif.

Read the full 85 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE